Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)

Pinder, Elizabeth M.; Atwal, Gurprit S. S.; Ayantunde, Abraham A.; Khan, Sarah; Sokal, Mike; McCulloch, Tom; Parsons, Simon L.

doi:https://doi.org/10.1155/2007/82012

Sarcoma

On this page

Abstract References Copyright Related Articles

Case Report | Open Access

Volume 2007 | Article ID 082012 | https://doi.org/10.1155/2007/82012

Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)

Elizabeth M. Pinder,¹Gurprit S. S. Atwal,²Abraham A. Ayantunde,¹Sarah Khan,³Mike Sokal,³Tom McCulloch,²and Simon L. Parsons¹

Academic Editor: Penella Woll

Received30 Nov 2006

Revised07 Apr 2007

Accepted15 Jun 2007

Published15 Nov 2007

Abstract

Tumour lysis syndrome (TLS) is a rare side effect of chemotherapy for solid tumours. It describes the metabolic derangements following rapid and extensive tumour cell death following a good response to chemotherapy. Symptoms are those of metabolic derangement and renal failure. Treatment involves rehydration and correction of metabolic abnormalities. TLS should be considered in high risk groups. We report a case of TLS in a patient with metastatic gastrointestinal stromal tumour treated with imatinib mesylate. To our knowledge, this is the first reported case.

References

J. Rosai, “GIST: an update,” International Journal of Surgical Pathology, vol. 11, no. 3, pp. 177–186, 2003.
View at: Publisher Site | Google Scholar
F. Duffaud and J.-Y. Blay, “Gastrointestinal stromal tumors: biology and treatment,” Oncology, vol. 65, no. 3, pp. 187–197, 2003.
View at: Publisher Site | Google Scholar
R. P. Dematteo, M. C. Heinrich, W. M. El-Rifai, and G. Demetri, “Clinical management of gastrointestinal stromal tumors: before and after STI-571,” Human Pathology, vol. 33, no. 5, pp. 466–477, 2002.
View at: Publisher Site | Google Scholar
A. T. van Oosterom, I. Judson, J. Verweij et al., “Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study,” The Lancet, vol. 358, no. 9291, pp. 1421–1423, 2001.
View at: Publisher Site | Google Scholar
H. Joensuu, P. J. Roberts, M. Sarlomo-Rikala et al., “Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor,” New England Journal of Medicine, vol. 344, no. 14, pp. 1052–1056, 2001.
View at: Publisher Site | Google Scholar
L. Baeksgaard and J. B. Sørensen, “Acute tumor lysis syndrome in solid tumors—a case report and review of the literature,” Cancer Chemotherapy and Pharmacology, vol. 51, no. 3, pp. 187–192, 2003.
View at: Publisher Site | Google Scholar
R. P. DeMatteo, J. J. Lewis, D. Leung, S. S. Mudan, J. M. Woodruff, and M. F. Brennan, “Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival,” Annals of Surgery, vol. 231, no. 1, pp. 51–58, 2000.
View at: Publisher Site | Google Scholar
M. H. Shiu, G. H. Farr, D. N. Papachristou, and S. I. Hajdu, “Myosarcomas of the stomach: natural history, prognostic factors and management,” Cancer, vol. 49, no. 1, pp. 177–187, 1982.
View at: Publisher Site | Google Scholar
A. Vora, M. Bhutani, A. Sharma, and V. Raina, “Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase,” Annals of Oncology, vol. 13, no. 11, pp. 1833–1834, 2002.
View at: Publisher Site | Google Scholar
M. S. Cairo and M. Bishop, “Tumour lysis syndrome: new therapeutic strategies and classification,” British Journal of Haematology, vol. 127, no. 1, pp. 3–11, 2004.
View at: Publisher Site | Google Scholar
S. Sallan, “Management of acute tumor lysis syndrome,” Seminars in Oncology, vol. 28, no. 2, supplement 5, pp. 9–12, 2001.
View at: Publisher Site | Google Scholar
R. V. Smalley, A. Guaspari, S. Haase-Statz, S. A. Anderson, D. Cederberg, and J. A. Hohneker, “Allopurinol: intravenous use for prevention and treatment of hyperuricaemia,” Journal of Clinical Oncology, vol. 18, no. 8, pp. 1758–1763, 2000.
View at: Google Scholar
P. R. Band, D. S. Silverberg, J. F. Henderson et al., “Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol,” New England Journal of Medicine, vol. 283, no. 7, pp. 354–357, 1970.
View at: Google Scholar
S. C. Goldman, J. S. Holcenberg, J. Z. Finklestein et al., “A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis,” Blood, vol. 97, no. 10, pp. 2998–3003, 2001.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2007 Elizabeth M. Pinder et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

479

Downloads

851

Citations